Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Soleno Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Soleno Therapeutics, Inc.’s stock price such as:

• Soleno Therapeutics, Inc.’s current stock price and volume
• Why Soleno Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SLNO from analysts
• SLNO’s stock price momentum as measured by its relative strength

About Soleno Therapeutics, Inc. (SLNO)

Before we jump into Soleno Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Want to learn more about Soleno Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Soleno Therapeutics, Inc..

Soleno Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 12:59 PM, CST, Soleno Therapeutics, Inc.’s stock price was $50.450.

Soleno Therapeutics, Inc. is up 1.82% from its previous closing price of $49.550.

During the last market session, Soleno Therapeutics, Inc.’s stock traded between $49.630 and $51.110. Currently, there are approximately 53.33 million shares outstanding for Soleno Therapeutics, Inc..

Soleno Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Soleno Therapeutics, Inc. Stock Price History

Soleno Therapeutics, Inc.’s (SLNO) price is currently down 24.88% so far this month.

During the month of November, Soleno Therapeutics, Inc.’s stock price has reached a high of $69.990 and a low of $41.800.

Over the last year, Soleno Therapeutics, Inc. has hit prices as high as $90.320 and as low as $41.500. Year to date, Soleno Therapeutics, Inc.’s stock is up 12.24%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Soleno Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were analysts who downgraded Soleno Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Soleno Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Soleno Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Soleno Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Soleno Therapeutics, Inc. (SLNO) by visiting AAII Stock Evaluator.

Relative Price Strength of Soleno Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Soleno Therapeutics, Inc. has a weighted four-quarter relative price strength of -6.74%, which translates to a Momentum Score of 35 and is considered to be Weak.

Want to learn more about how Soleno Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Soleno Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, Soleno Therapeutics, Inc.’s stock price is $50.450, which is up 1.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Soleno Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.